Trial Outcomes & Findings for Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area (NCT NCT01426373)
NCT ID: NCT01426373
Last Updated: 2016-01-14
Results Overview
Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?"
COMPLETED
PHASE3
165 participants
Up to 12 months after last treatment (maximum of 18 months from first treatment)
2016-01-14
Participant Flow
The study was conducted at 18 investigational centers in the United States.
Participant milestones
| Measure |
Deoxycholic Acid 2 mg/cm²
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
|---|---|
|
Overall Study
STARTED
|
165
|
|
Overall Study
COMPLETED
|
131
|
|
Overall Study
NOT COMPLETED
|
34
|
Reasons for withdrawal
| Measure |
Deoxycholic Acid 2 mg/cm²
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
|---|---|
|
Overall Study
Adverse Event
|
6
|
|
Overall Study
Lost to Follow-up
|
14
|
|
Overall Study
Participant Convenience
|
10
|
|
Overall Study
Miscellaneous Reasons
|
4
|
Baseline Characteristics
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Baseline characteristics by cohort
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
|---|---|
|
Age, Continuous
|
46.9 years
STANDARD_DEVIATION 10.89 • n=99 Participants
|
|
Age, Customized
18 - 50 years
|
98 participants
n=99 Participants
|
|
Age, Customized
51 - 65 years
|
63 participants
n=99 Participants
|
|
Age, Customized
> 65 years
|
4 participants
n=99 Participants
|
|
Sex: Female, Male
Female
|
128 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=99 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
1 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Asian
|
7 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
15 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
1 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Other
|
12 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
White
|
129 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latino
|
30 participants
n=99 Participants
|
|
Race/Ethnicity, Customized
Not Hispanic or Latino
|
135 participants
n=99 Participants
|
|
Weight
|
80.37 kg
STANDARD_DEVIATION 15.111 • n=99 Participants
|
|
Body Mass Index (BMI)
|
28.88 kg/m²
STANDARD_DEVIATION 4.311 • n=99 Participants
|
|
Fitzpatrick Skin Type
I - III
|
123 participants
n=99 Participants
|
|
Fitzpatrick Skin Type
IV - VI
|
42 participants
n=99 Participants
|
|
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
2
|
86 participants
n=99 Participants
|
|
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
3
|
66 participants
n=99 Participants
|
|
Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating
4
|
13 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Up to 12 months after last treatment (maximum of 18 months from first treatment)Population: Safety population
Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?"
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Number of Participants With Adverse Events (AEs)
Any adverse event
|
160 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Serious adverse event
|
7 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Severe adverse event
|
11 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Adverse event leading to withdrawal from treatment
|
15 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Adverse event leading to study discontinuation
|
6 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Adverse event leading to death
|
1 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Adverse event related to study drug
|
155 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Serious adverse event related to study drug
|
0 participants
|
—
|
|
Number of Participants With Adverse Events (AEs)
Adverse event associated with the treatment area
|
158 participants
|
—
|
SECONDARY outcome
Timeframe: Baseline and months 3, 6, 9, and 12 after last treatmentPopulation: Treatment effect population (all participants who received at least 1 injection with study drug and had any posttreatment data for treatment effect variables or for the submental skin laxity grade) and with available data at each time point (indicated by "n").
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). A negative change from baseline indicates improvement.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 3 after last treatment (n = 144)
|
-1.3 units on a scale
Standard Deviation 0.85
|
—
|
|
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 6 after last treatment (n = 133)
|
-1.3 units on a scale
Standard Deviation 0.85
|
—
|
|
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 9 after last treatment (n = 134)
|
-1.4 units on a scale
Standard Deviation 0.81
|
—
|
|
Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS)
Month 12 after last treatment (n = 131)
|
-1.4 units on a scale
Standard Deviation 0.80
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline (163) and at each time point (indicated by "n")
The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). A negative change from baseline indicates improvement.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
Month 3 after last treatment (n = 142)
|
-1.2 units on a scale
Standard Deviation 0.90
|
—
|
|
Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS)
Month 12 after last treatment (n = 127)
|
-1.3 units on a scale
Standard Deviation 0.88
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline and at each time point (indicated by "n")
A composite 1-grade response is defined as at least a 1-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat).
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Percentage of Participants Who Achieved a Composite 1-grade Response
Month 3 after last treatment (n = 142)
|
72.5 percentage of participants
|
—
|
|
Percentage of Participants Who Achieved a Composite 1-grade Response
Month 12 after last treatment (n = 128)
|
75.0 percentage of participants
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline and at each time point (indicated by "n")
A composite 2-grade response is defined as at least a 2-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat).
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Percentage of Participants Who Achieved a Composite 2-grade Response
Month 3 after last treatment (n = 142)
|
14.1 percentage of participants
|
—
|
|
Percentage of Participants Who Achieved a Composite 2-grade Response
Month 12 after last treatment (n = 128)
|
20.3 percentage of participants
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline and each time point (indicated by "n")
The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from baseline indicates improvement.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
Month 3 after last treatment (n = 145)
|
-4.3 units on a scale
Standard Deviation 2.86
|
—
|
|
Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
Month 12 after last treatment (n = 129)
|
-4.2 units on a scale
Standard Deviation 2.86
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data (indicated by "n")
The SSRS assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 (0 = extremely dissatisfied, 1 = dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly satisfied, 5 = satisfied and 6 = extremely satisfied). A positive change from baseline indicates improvement.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Mean Change From Baseline in Subject Self Rating Scale (SSRS)
Month 3 after last treatment (n = 144)
|
3.6 units on a scale
Standard Deviation 1.49
|
—
|
|
Mean Change From Baseline in Subject Self Rating Scale (SSRS)
Month 12 after last treatment (n = 128)
|
3.8 units on a scale
Standard Deviation 1.36
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline (163), month 3 (144), and month 12 (130)
Self-rating of Attractiveness assesses aspects of appearance from the participant's perspective with a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 (1 = not at all attractive, 5 = neither attractive nor unattractive, and 9 = extremely attractive). A positive change from baseline indicates improvement.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=163 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Mean Change From Baseline in Self-rating of Attractiveness
Overall appearance - month 3 after last treatment
|
0.8 units on a scale
Standard Deviation 1.53
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Overall appearance - month 12 after last treatment
|
1.0 units on a scale
Standard Deviation 1.62
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Chin/neck - month 3 after last treatment
|
2.6 units on a scale
Standard Deviation 2.35
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Chin/neck - month 12 after last treatment
|
3.1 units on a scale
Standard Deviation 2.43
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Eyes - month 3 after last treatment
|
0.4 units on a scale
Standard Deviation 1.62
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Eyes - month 12 after last treatment
|
0.6 units on a scale
Standard Deviation 1.70
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Nose - month 3 after last treatment
|
0.3 units on a scale
Standard Deviation 1.66
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Nose - month 12 after last treatment
|
0.6 units on a scale
Standard Deviation 1.97
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Mouth - month 3 after last treatment
|
0.3 units on a scale
Standard Deviation 1.45
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Mouth - month 12 after last treatment
|
0.6 units on a scale
Standard Deviation 1.44
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Entire face - month 3 after last treatment
|
0.5 units on a scale
Standard Deviation 1.27
|
—
|
|
Mean Change From Baseline in Self-rating of Attractiveness
Entire face - month 12 after last treatment
|
0.8 units on a scale
Standard Deviation 1.28
|
—
|
SECONDARY outcome
Timeframe: Month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at each time point
Participants answered 3 questions on a 7-point scale that ranged from "a great deal worse" to "a great deal better" (questions 1 and 2) or from "extremely dissatisfied" to "extremely satisfied" (question 3). Question 1: Since the start of the study, how would you rate the fat under your chin right now? Question 2: Since the start of the study, how would you rate the definition between your chin and neck right now? Question 3: How satisfied are you with the treatment you received in this study?
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=145 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
n=130 Participants
|
|---|---|---|
|
Response to Subject Global Questions
Question 1 - a great deal worse
|
0 participants
|
0 participants
|
|
Response to Subject Global Questions
Question 1 - moderately worse
|
1 participants
|
1 participants
|
|
Response to Subject Global Questions
Question 1 - a little worse
|
0 participants
|
1 participants
|
|
Response to Subject Global Questions
Question 1 - about the same
|
6 participants
|
7 participants
|
|
Response to Subject Global Questions
Question 1 - a little better
|
22 participants
|
23 participants
|
|
Response to Subject Global Questions
Question 1 - moderately better
|
48 participants
|
32 participants
|
|
Response to Subject Global Questions
Question 1 - a great deal better
|
68 participants
|
66 participants
|
|
Response to Subject Global Questions
Question 2 - a great deal worse
|
0 participants
|
0 participants
|
|
Response to Subject Global Questions
Question 2 - moderately worse
|
0 participants
|
1 participants
|
|
Response to Subject Global Questions
Question 2 - a little worse
|
0 participants
|
0 participants
|
|
Response to Subject Global Questions
Question 2 - about the same
|
5 participants
|
5 participants
|
|
Response to Subject Global Questions
Question 2 - a little better
|
27 participants
|
27 participants
|
|
Response to Subject Global Questions
Question 2 - moderately better
|
53 participants
|
38 participants
|
|
Response to Subject Global Questions
Question 2 - a great deal better
|
60 participants
|
59 participants
|
|
Response to Subject Global Questions
Question 3 - extremely dissatisfied
|
1 participants
|
1 participants
|
|
Response to Subject Global Questions
Question 3 - moderately dissatisfied
|
0 participants
|
1 participants
|
|
Response to Subject Global Questions
Question 3 - a little dissatisfied
|
2 participants
|
2 participants
|
|
Response to Subject Global Questions
Question 3 - neither dissatisfied nor satisfied
|
5 participants
|
6 participants
|
|
Response to Subject Global Questions
Question 3 - a little satisfied
|
15 participants
|
11 participants
|
|
Response to Subject Global Questions
Question 3 - moderately satisfied
|
43 participants
|
30 participants
|
|
Response to Subject Global Questions
Question 3 - extremely satisfied
|
79 participants
|
79 participants
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data at baseline (164) and at each time point
Submental fat thickness was measured using calipers.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=164 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Percent Change From Baseline in Submental Fat Thickness
Month 3 after last treatment (n = 144)
|
-27.2 percent change
Standard Deviation 21.82
|
—
|
|
Percent Change From Baseline in Submental Fat Thickness
Month 12 after last treatment (n = 131)
|
-30.9 percent change
Standard Deviation 20.88
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 and month 12 after last treatmentPopulation: Treatment effect population with available data (indicated by "n")
SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds)); Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging); Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging); Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging).
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Change From Baseline in Submental Skin Laxity Grade (SMSLG)
Month 3 after last treatment (n = 144)
|
-0.3 units on a scale
Standard Deviation 0.58
|
—
|
|
Change From Baseline in Submental Skin Laxity Grade (SMSLG)
Month 12 after last treatment (n = 131)
|
-0.3 units on a scale
Standard Deviation 0.63
|
—
|
SECONDARY outcome
Timeframe: Baseline and month 3 after last treatmentPopulation: Treatment effect population with available data
Each participant was given 2 example line drawings representing each of the 5 submental fat grades (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme) and asked to select the drawing that best represents their current profile. Improvement is any decrease in grade, and worsening is any increase in grade.
Outcome measures
| Measure |
Deoxycholic Acid 2 mg/cm²
n=143 Participants
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
Month 12 After Last Treatment
|
|---|---|---|
|
Change From Baseline in Line Drawing Assessment
Improved by > 2
|
27 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Improved by 2
|
52 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Improved by 1
|
25 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Unchanged
|
31 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Worsened by 1
|
8 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Worsened by 2
|
0 participants
|
—
|
|
Change From Baseline in Line Drawing Assessment
Worsened by > 2
|
0 participants
|
—
|
Adverse Events
Deoxycholic Acid 2 mg/cm²
Serious adverse events
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 participants at risk
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Cardiac death
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Infections and infestations
Diverticulitis
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Psychiatric disorders
Anxiety
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Reproductive system and breast disorders
Cervical polyp
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Surgical and medical procedures
Stent placement
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Vascular disorders
Arteriosclerosis
|
0.61%
1/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
Other adverse events
| Measure |
Deoxycholic Acid 2 mg/cm²
n=165 participants at risk
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
|
|---|---|
|
General disorders
Injection site hematoma
|
73.3%
121/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site anesthesia
|
70.3%
116/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site pain
|
68.5%
113/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site edema
|
67.3%
111/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site erythema
|
50.3%
83/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site induration
|
37.0%
61/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site swelling
|
29.7%
49/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site pruritus
|
21.8%
36/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site nodule
|
19.4%
32/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
General disorders
Injection site paresthesia
|
18.8%
31/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Nervous system disorders
Headache
|
9.1%
15/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Investigations
Blood triglycerides increased
|
7.3%
12/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
|
Investigations
Blood glucose increased
|
5.5%
9/165 • Up to 12 months after last treatment (maximum of 18 months from first treatment)
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The clinical study agreement requires that the investigator or institution obtain written consent from Kythera Biopharmaceuticals, Inc. prior to presenting and/or publishing results of this study.
- Publication restrictions are in place
Restriction type: OTHER